Issue 5/2017
Content (16 Articles)
The potential of multi-compound nanoparticles to bypass drug resistance in cancer
C. G. Da Silva, Godefridus J. Peters, Ferry Ossendorp, Luis J. Cruz
Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management
Bryan Oronsky, Scott Caroen, Arnold Oronsky, Vaughn E. Dobalian, Neil Oronsky, Michelle Lybeck, Tony R. Reid, Corey A. Carter
Regulation of paclitaxel activity by microtubule-associated proteins in cancer chemotherapy
Xingjuan Shi, Xiaoou Sun
Animals living in polluted environments are a potential source of anti-tumor molecule(s)
Shareni Jeyamogan, Naveed Ahmed Khan, Ruqaiyyah Siddiqui
Repositioning of proton pump inhibitors in cancer therapy
Zhen-Ning Lu, Bing Tian, Xiu-Li Guo
Multicenter phase II study of capecitabine plus cisplatin as first-line therapy for human epidermal growth factor receptor 2-negative advanced gastric cancer: Yokohama Clinical Oncology Group Study YCOG1107
Kei Sato, Chikara Kunisaki, Takashi Kosaka, Ryo Takagawa, Masazumi Takahashi, Yusuke Izumisawa, Hiroshi Miyamoto, Sho Sato, Yusaku Tanaka, Naotaka Yamaguchi, Jun Kimura, Hidetaka A. Ono, Hirochika Makino, Hirotoshi Akiyama, Itaru Endo
Regorafenib in advanced hepatocellular carcinoma (HCC): considerations for treatment
Kyung Kim, Reena Jha, Petra A. Prins, Hongkun Wang, Monica Chacha, Marion L. Hartley, Aiwu Ruth He
A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002)
Yasuyuki Ikezawa, Hajime Asahina, Satoshi Oizumi, Masahiro Watanabe, Kei Takamura, Yasutaka Kawai, Noriyuki Yamada, Toshiyuki Harada, Ichiro Kinoshita, Yuka Fujita, Eisaku Miyauchi, Takahiro Ogi, Toraji Amano, Megumi Furuta, Jun Sakakibara-Konishi, Hiroshi Nishihara, Hirotoshi Dosaka-Akita, Hiroshi Isobe, Masaharu Nishimura
Innovative intraoral cooling device better tolerated and equally effective as ice cooling
Java Walladbegi, Martin Gellerstedt, Anncarin Svanberg, Mats Jontell
miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1
Haifeng Zhang, Baoli Hu, Zuopei Wang, Feng Zhang, Haitao Wei, Li Li
Participation of MT3 melatonin receptors in the synergistic effect of melatonin on cytotoxic and apoptotic actions evoked by chemotherapeutics
Roberto Pariente, Ignacio Bejarano, Javier Espino, Ana B. Rodríguez, José A. Pariente
Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab
Motoo Nomura, Atsushi Otsuka, Tomohiro Kondo, Hiroki Nagai, Yumi Nonomura, Yo Kaku, Shigemi Matsumoto, Manabu Muto
Phase I study of a chloroquine–gemcitabine combination in patients with metastatic or unresectable pancreatic cancer
Panagiotis Samaras, Marina Tusup, Thi Dan Linh Nguyen-Kim, Burkhardt Seifert, Helga Bachmann, Roger von Moos, Alexander Knuth, Steve Pascolo
A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification
Daniel Moj, Hannah Britz, Jürgen Burhenne, Clinton F. Stewart, Gerlinde Egerer, Walter E. Haefeli, Thorsten Lehr
Inhibitory growth evaluation and apoptosis induction in MCF-7 cancer cells by new 5-aryl-2-butylthio-1,3,4-oxadiazole derivatives
Rashmin Khanam, Kamal Ahmad, Iram I. Hejazi, Ibrar A. Siddique, Vikash Kumar, Abdul Roouf Bhat, Amir Azam, Fareeda Athar
Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma
Zhengqiu Zhou, Tracy A. Howard, John L. Villano